These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 18494740)

  • 1. Ischaemic change after intravitreal bevacizumab (Avastin) injection for macular oedema secondary to non-ischaemic central retinal vein occlusion.
    Kim KS; Chang HR; Song S
    Acta Ophthalmol; 2008 Dec; 86(8):925-7. PubMed ID: 18494740
    [No Abstract]   [Full Text] [Related]  

  • 2. Early intravitreal bevacizumab for non-ischaemic central retinal vein occlusion.
    Rensch F; Jonas JB; Spandau UH
    Acta Ophthalmol; 2009 Feb; 87(1):77-81. PubMed ID: 18937800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early intravitreal bevacizumab for non-ischaemic branch retinal vein occlusion.
    Rensch F; Jonas JB; Spandau UH
    Ophthalmologica; 2009; 223(2):124-7. PubMed ID: 19088494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion.
    Rosenfeld PJ; Fung AE; Puliafito CA
    Ophthalmic Surg Lasers Imaging; 2005; 36(4):336-9. PubMed ID: 16156153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial.
    Prager F; Michels S; Kriechbaum K; Georgopoulos M; Funk M; Geitzenauer W; Polak K; Schmidt-Erfurth U
    Br J Ophthalmol; 2009 Apr; 93(4):452-6. PubMed ID: 19074916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion.
    Kreutzer TC; Alge CS; Wolf AH; Kook D; Burger J; Strauss R; Kunze C; Haritoglou C; Kampik A; Priglinger S
    Br J Ophthalmol; 2008 Mar; 92(3):351-5. PubMed ID: 18211925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study.
    Kriechbaum K; Michels S; Prager F; Georgopoulos M; Funk M; Geitzenauer W; Schmidt-Erfurth U
    Br J Ophthalmol; 2008 Apr; 92(4):518-22. PubMed ID: 18211942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rebound of macular edema after intravitreal bevacizumab therapy in eyes with macular edema secondary to branch retinal vein occlusion.
    Yasuda S; Kondo M; Kachi S; Ito Y; Terui T; Ueno S; Terasaki H
    Retina; 2011 Jun; 31(6):1075-82. PubMed ID: 21478810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up.
    Wu L; Arevalo JF; Roca JA; Maia M; Berrocal MH; Rodriguez FJ; Evans T; Costa RA; Cardillo J;
    Retina; 2008 Feb; 28(2):212-9. PubMed ID: 18301025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retinal sensitivity after intravitreal injection of bevacizumab for the treatment of macular edema secondary to retinal vein occlusion.
    Yamaike N; Tsujikawa A; Sakamoto A; Ota M; Kotera Y; Miyamoto K; Kita M; Yoshimura N
    Retina; 2009 Jun; 29(6):757-67. PubMed ID: 19289982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal bevacizumab treatment of macular oedema due to central retinal vein occlusion.
    Spandau UH; Ihloff AK; Jonas JB
    Acta Ophthalmol Scand; 2006 Aug; 84(4):555-6. PubMed ID: 16879582
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to central retinal vein occlusion: results of the pan American collaborative retina study group at 24 months.
    Wu L; Arevalo JF; Berrocal MH; Maia M; Roca JA; Morales-Cantón V; Alezzandrini AA; Díaz-Llopis MJ
    Retina; 2010; 30(7):1002-11. PubMed ID: 20616679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term safety and efficacy of intravitreal bevacizumab (Avastin) for the management of central retinal vein occlusion.
    Gregori NZ; Gaitan J; Rosenfeld PJ; Puliafito CA; Feuer W; Flynn HW; Berrocal AM; Al-Attar L; Dubovy S; Smiddy WE; Schwartz SG; Lee WH; Murray TG
    Retina; 2008 Oct; 28(9):1325-37. PubMed ID: 19430392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of three different intravitreal treatment modalities of macular edema due to branch retinal vein occlusion.
    Cekiç O; Cakır M; Yazıcı AT; Alagöz N; Bozkurt E; Faruk Yılmaz O
    Curr Eye Res; 2010 Oct; 35(10):925-9. PubMed ID: 20858114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study.
    Costa RA; Jorge R; Calucci D; Melo LA; Cardillo JA; Scott IU
    Retina; 2007 Feb; 27(2):141-9. PubMed ID: 17290194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to branch retinal vein occlusions: results of the Pan American Collaborative Retina Study Group at 24 months.
    Wu L; Arevalo JF; Berrocal MH; Maia M; Roca JA; Morales-Cantón V; Alezzandrini AA; Díaz-Llopis MJ
    Retina; 2009; 29(10):1396-403. PubMed ID: 19898177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal injection of bevacizumab for macular edema secondary to branch retinal vein occlusion:results after 12 months and multiple regression analysis.
    Kondo M; Kondo N; Ito Y; Kachi S; Kikuchi M; Yasuma TR; Ota I; Kensaku M; Terasaki H
    Retina; 2009 Oct; 29(9):1242-8. PubMed ID: 19672216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravitreal bevacizumab vs triamcinolone acetonide for macular oedema due to central retinal vein occlusion.
    Tao Y; Hou J; Jiang YR; Li XX; Jonas JB
    Eye (Lond); 2010 May; 24(5):810-5. PubMed ID: 19696805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of branch retinal vein occlusion induced macular edema with bevacizumab.
    Abegg M; Tappeiner C; Wolf-Schnurrbusch U; Barthelmes D; Wolf S; Fleischhauer J
    BMC Ophthalmol; 2008 Sep; 8():18. PubMed ID: 18823536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of intravitreal bevacizumab (avastin) for the management of branch and hemiretinal vein occlusion.
    Gregori NZ; Rattan GH; Rosenfeld PJ; Puliafito CA; Feuer W; Flynn HW; Berrocal AM; Al-Attar L; Dubovy S; Smiddy WE; Schwartz SG; Lee WH; Murray TG
    Retina; 2009; 29(7):913-25. PubMed ID: 19584649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.